Decoy Therapeutics to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull Financial

Company Overview - Decoy Therapeutics, Inc. is a preclinical-stage biotechnology company focused on developing peptide conjugate therapeutics targeting serious unmet medical needs, particularly in respiratory viruses and gastrointestinal cancers [3] - The company utilizes machine learning and artificial intelligence tools alongside high-speed synthesis techniques to design and manufacture its drug candidates [3] - Decoy has secured financing from institutional investors and non-dilutive capital sources, including the Massachusetts Life Sciences Seed Fund, Google AI startup program, and NVIDIA Inception program [3] Upcoming Presentation - Decoy Therapeutics will participate in the Corporate Connect Webinar Series hosted by Webull Financial on February 10-11, 2026 [1] - Rick Pierce, the CEO of Decoy Therapeutics, will provide a corporate overview and discuss a new class of antiviral therapeutics capable of targeting multiple viral pathogens with a single drug [2] Financial and Strategic Partnerships - The company has received funding from the Biomedical Advanced Research and Development Authority (BARDA) through the QuickFire Challenge award, in collaboration with Johnson & Johnson Innovation – JLABS [3]